Eli Lilly and Company $LLY Stock Holdings Boosted by S Bank Fund Management Ltd

S Bank Fund Management Ltd grew its holdings in Eli Lilly and Company (NYSE:LLY) by 39.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,778 shares of the company’s stock after buying an additional 7,846 shares during the quarter. Eli Lilly and Company accounts for 2.8% of S Bank Fund Management Ltd’s investment portfolio, making the stock its 6th largest position. S Bank Fund Management Ltd’s holdings in Eli Lilly and Company were worth $21,195,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at about $29,000. Steph & Co. boosted its holdings in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter worth about $31,000. Finally, Bare Financial Services Inc raised its holdings in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s announced acquisition of Ventyx Biosciences offered a strategic complement to its weight‑loss franchise by targeting inflammation (data showed benefit when combined with GLP‑1 therapy); the deal helped calm investor concern after the Novo news and supported a rally. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
• Positive Sentiment: Lilly and NVIDIA will fund a $1B AI co‑innovation lab over five years to speed drug discovery and manufacturing—this could lower R&D costs and shorten time‑to‑market for new drugs, a multi‑year positive for pipeline value. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Commercial demand traction: Humana’s CenterWell Pharmacy launching an employer program that uses Lilly’s GLP‑1 drugs underscores ongoing demand and distribution pathways for Lilly’s marketed products. Humana’s CenterWell Pharmacy Launches Employer Venture Using Lilly’s GLP-1 Drugs
• Neutral Sentiment: Company guidance and seasonality: Analysts expect double‑digit Q4 growth and Lilly has strong FY 2025/26 earnings expectations—these set a positive baseline but already appear priced into the stock. What to Expect From Eli Lilly’s Q4 2025 Earnings Report
• Neutral Sentiment: Lilly says it is confident about supply readiness for its oral weight‑loss candidate ahead of an anticipated U.S. approval—reduces one operational risk but doesn’t remove competitive or regulatory uncertainty. Lilly says it’s confident in weight-loss pill supply ahead of U.S. approval
• Negative Sentiment: Competitive pressure: Novo Nordisk’s immediate nationwide rollout of the Wegovy oral pill surprised some investors and triggered a pullback in LLY shares as markets priced higher competition in the oral GLP‑1 market. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

Eli Lilly and Company Trading Down 0.5%

Shares of LLY stock opened at $1,075.90 on Wednesday. The company’s 50-day moving average price is $1,044.24 and its 200-day moving average price is $865.79. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.64, a PEG ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the business earned $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LLY. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. UBS Group initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 target price for the company. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Thursday, December 4th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.